Atlanta Center for Medical Research

The Atlanta Center for Medical Research’s founder, Dr. Robert A. Riesenberg, earned his MD in psychiatry in 1975, when biological psychiatric research was in its infancy. He was exhilarated by the possibility that many intractable psychiatric illnesses could be treated with medication. What medicines might help people suffering from schizophrenia or depression? Might there be a better way to diagnose and help those suffering from PTSD? These questions and many others fascinated Dr. Riesenberg, and the opportunity to peer deeply into human-drug interaction was irresistible.

Dr. Riesenberg initially divided his time between private psychiatric practice and research, but as his medical research business grew, he was soon able to devote himself entirely to research. He began assembling a research team of the nation’s top research investigators, doctors, nurses, coordinators, pharmacists, technicians, and research assistants.

ACMR was initially exclusively dedicated to biological psychiatric research, but it soon broadened its focus to include all medical research concerned with the central nervous system. Today, ACMR brings its expertise to all areas of medical research from phase 0/1 first-in-human trials all the way through phase 4 trials of both medical and behavioral treatments.

ACMR was soon one of the top medical research institutions in the country. Five times now, ACMR has relocated to larger facilities to accommodate growing demand, and each time it has taken the opportunity to raise industry standards for what a medical research facility should be. The latest relocation is by far the organization’s most ambitious yet. Rebuilt from the ground up in a former hospital, the 150,000-square-foot Atlanta Center for Medical Research is the physical manifestation of our more than three decades of research expertise, with every design decision made with research needs in mind.

“You finish each day feeling verified that you’ve done something that can make a difference. Our people work very hard. The payoff for our work is that we feel very strongly that we’re doing something good for our participants and for medicine in general. There’s no other way to get a medicine on the market.”

Our state-of-the-art research facility and industry-leading staff allow the organization to offer virtually any service a study requires, and the center is administered by specialists experienced in the unique requirements of medical research. The center has its own study imaging department, compounding research pharmacy, biomedical technicians, study sample processing and storage area, biorepository, and, out of an abundance of caution for participant safety, even a level 2 trauma center and a medevac helipad. If there’s a service needed for medical research, it is almost certainly provided at the ACMR facility.

ACMR’s open-source facility and services are also available to third-party medical research organizations and independent investigators who are conducting research under an FDA-approved protocol. This first-of-its-kind, game-changing model for a research facility empowers any investigator to conduct research at the same world-class level that sponsors have come to expect of ACMR, bringing more, better medicines safely to market.

ACMR has a long working history with major medicine companies and is trusted by contract research organizations such as:

  • Abbott
  • AbbVie
  • Alkermes
  • AstraZeneca
  • Bayer
  • Corcept
  • Eli Lilly
  • Forest
  • Forum
  • GlaxoSmithKline
  • ICON
  • I3 Research
  • Janssen
  • Johnson & Johnson
  • Lundbeck
  • Merck
  • Naurex
  • Neos
  • Novartis
  • Organon
  • Otsuka
  • Parexel
  • Pfizer
  • Quintiles
  • Roche
  • Scirex
  • Shire
  • Sunovion
  • Takeda
  • Teva
  • US WorldMeds
  • Wyeth

Learn more about ACMR’s research services to see how ACMR can help you.

ACMR uses cookies to collect information on how visitors behave on our website. The information we collect will not be linked with a visitor's identity.
By continuing to use our website, you agree to our use of cookies.